Posted by Michael Wonder on 04 Jun 2017
Measuring value and benefit—a matter of perspective
2 June 2017 - There is growing concern about the sustainability of health-care systems as the populations of high-income countries age and increasingly expensive medical technologies proliferate. Drug costs are rising faster than those for other segments of the health care sector.
The average price of new anticancer drugs now commonly exceeds US$10 000/month, with incremental price increases seemingly disproportionate to the incremental benefit attained.
Thus, interest has grown in formally measuring improvements in outcomes relative to the costs of cancer interventions to determine the value of different treatments.
